1. Naltrexone plus bupropion reduces cigarette smoking in individuals with methamphetamine use disorder: A secondary analysis from the CTN ADAPT-2 trial
- Author
-
Schmitz, Joy M, Stotts, Angela L, Yoon, Jin H, Northrup, Thomas F, Villarreal, Yolanda R, Yammine, Luba, Weaver, Michael F, Carmody, Thomas, Shoptaw, Steven, and Trivedi, Madhukar H
- Subjects
Biological Psychology ,Psychology ,Clinical Research ,Prevention ,Tobacco ,Substance Misuse ,Tobacco Smoke and Health ,Health Disparities ,Clinical Trials and Supportive Activities ,Drug Abuse (NIDA only) ,Methamphetamine ,Brain Disorders ,Women's Health ,6.1 Pharmaceuticals ,Cancer ,Respiratory ,Good Health and Well Being ,Humans ,Naltrexone ,Bupropion ,Cigarette Smoking ,Narcotic Antagonists ,Prospective Studies ,Tobacco use ,ADAPT-2 trial ,Co-occurring substances ,Combination pharmacotherapy - Abstract
IntroductionMethamphetamine (MA) use is marked by high rates of comorbid tobacco smoking, which is associated with more severe drug use and worse clinical outcomes compared to single use of either drug. Research has shown the combination of naltrexone plus oral bupropion (NTX-BUP) improves smoking cessation outcomes in non-MA-using populations. In the Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) study, NTX-BUP successfully reduced MA use. Our aim in this secondary data analysis was to examine changes in cigarette smoking among the subgroup of participants reporting comorbid tobacco use in the ADAPT-2 trial.MethodsThe multi-site ADAPT-2 study used a randomized, double blind, sequential parallel comparison design to evaluate treatment with extended-release injectable NTX (380 mg every 3 weeks) combined with once-daily oral extended-release BUP (450 mg/day) vs matching injectable and oral placebo in outpatients with moderate or severe MA use disorder. The study assessed smoking outcomes, based on self-reported timeline followback (TLFB) data, twice/week for 13 weeks.ResultsOf the 403 participants in the ADAPT-2 trial, 290 reported being current cigarette smokers (71.9 %). The study found significant differences (p's
- Published
- 2023